10. The fiber according to claim 2, wherein n is from 50 to 200, a is at least 0.15.

11. The fiber according to claim 2, wherein n is from 50 to 200, a is at least 0.5.

12. The fiber according to claim 1, wherein R_3 and R_4 are $(CH_3)_2CH—CH_2—$; and R_7 is benzyl.

13. The fiber according to claim 1, wherein R_1 is $—(CH_2)_8—$; R_3 and R_4 are $(CH_3)_2CH—CH_2—$; and R_7 is benzyl.

14. The fiber according to claim 7, wherein R_3 and R_4 are $(CH_3)_2CH—CH_2—$; and R_7 is benzyl.

15. The fiber according to claim 7, wherein R_1 is $—(CH_2)_8—$; R_3 and R_4 are $(CH_3)_2CH—CH_2—$; and R_7 is benzyl.

16. The fiber according to claim 1, wherein the cylindrical core comprises a side and two ends, and wherein the shell surrounds the side and one end of the cylindrical core, and the shell does not surround one end of the cylindrical core.

17. The fiber according to claim 1, wherein the cylindrical core comprises a side and two ends, and wherein the shell surrounds the side of the cylindrical core, and the shell does not surround the ends of the cylindrical core.

18. The fiber according to claim 14, wherein the cylindrical core comprises a side and two ends, and wherein the shell surrounds the side of the cylindrical core, and the shell does not surround the ends of the cylindrical core.

19. The fiber according to claim 1, wherein the fiber has an average diameter of from 50 to 500 μm and the shell has a thickness of between 0.5 and 5 μm.

20. The fiber according to claim 1, wherein the core consists of the polyesteramide copolymer, the bioactive agent, and optionally an excipient.

21. The fiber according to claim 1, wherein the shell consists of the polyesteramide copolymer.

22. The fiber according to claim 20, wherein the shell consists of the polyesteramide copolymer.

23. The fiber according to claim 14, wherein the bioactive agent comprises latanoprost, bimatoprost or travoprost.

24. The fiber according to claim 22, wherein the bioactive agent comprises latanoprost, bimatoprost or travoprost.

25. A method for treating glaucoma, ocular hypertension, diabetic retinopathy or macular degeneration comprising the step of injecting the fiber according to claim 1 into the eye or subconjunctival space of a mammal in need of treatment thereof.

26. A method for treating glaucoma, ocular hypertension, diabetic retinopathy or macular degeneration comprising the step of injecting the fiber according to claim 5 into the eye or subconjunctival space of a mammal in need of treatment thereof.

27. A method for treating glaucoma, ocular hypertension, diabetic retinopathy or macular degeneration comprising the step of injecting the fiber according to claim 23 into the eye or subconjunctival space of a mammal in need of treatment thereof.

28. A method for treating glaucoma, ocular hypertension, diabetic retinopathy or macular degeneration comprising the step of injecting the fiber according to claim 24 into the eye or subconjunctival space of a mammal in need of treatment thereof.

* * * * *